AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer
Days After Green Light For Clovis's Rival PARP
Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.
